Drug Type Monoclonal antibody |
Synonyms JNJ-2761, JNJ2761, JNJ87562761 |
Target |
Action inhibitors |
Mechanism GPRC5D inhibitors(G-protein coupled receptor family C group 5member D inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (United States) |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Refractory Multiple Myeloma | Phase 1 | Canada | 19 Dec 2024 | |
| Refractory Multiple Myeloma | Phase 1 | South Korea | 19 Dec 2024 | |
| Refractory Multiple Myeloma | Phase 1 | Spain | 19 Dec 2024 | |
| Refractory Multiple Myeloma | Phase 1 | Taiwan Province | 19 Dec 2024 | |
| Relapse multiple myeloma | Phase 1 | Canada | 19 Dec 2024 | |
| Relapse multiple myeloma | Phase 1 | South Korea | 19 Dec 2024 | |
| Relapse multiple myeloma | Phase 1 | Spain | 19 Dec 2024 | |
| Relapse multiple myeloma | Phase 1 | Taiwan Province | 19 Dec 2024 |






